Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 1:10 p.m. EST. Daniel Swisher, President and COO, will provide a company overview and financial update. Interested parties can access the live audio webcast through the Jazz Pharmaceuticals website, where an archive will be available for one week post-event. The company focuses on developing innovative medicines for serious diseases in neuroscience and oncology, serving patients across more than 90 countries.

Positive

• Scheduled presentation at a prominent healthcare conference may enhance visibility.
• Presentation by a senior executive may provide valuable insights to investors.

Negative

• None.

DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference:

• Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:10 p.m. EST / 6:10 p.m. GMT. Daniel Swisher, president and chief operating officer, will provide an overview of the company and a business and financial update.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available following the presentation for at least one week on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases — often with limited or no options.  We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas.  Our focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic malignancies and solid tumors. We actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies.  Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.  For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Jazz Pharmaceuticals Contacts:
Investors:  Kathee Littrell Vice President, Investor Relations Ireland +353 1 634 7887 U.S. +1 650 496 2717	Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Ireland +353 1 697 2141 U.S. +1 215 867 4910

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-at-jefferies-virtual-london-healthcare-conference-301170204.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals' presentation at the Jefferies Virtual London Healthcare Conference?

The presentation is scheduled for November 17, 2020, at 1:10 p.m. EST.

Who will represent Jazz Pharmaceuticals at the conference?

Daniel Swisher, President and COO, will represent the company.

Where can I access the webcast of Jazz Pharmaceuticals' presentation?

The webcast can be accessed on the Investors section of the Jazz Pharmaceuticals website.

How long will the archive of the webcast be available?

The archive will be available for at least one week following the presentation.

What areas does Jazz Pharmaceuticals focus on?

The company focuses on neuroscience and oncology in its drug development efforts.